Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin and Rituximab in Post Transplant Lymphoproliferative Disease
NCT00064246Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2003
- Primary completion
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by National Cancer Institute. Started Jul 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT00064246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064246.